NASDAQ:ABUS
Arbutus Biopharma Corporation Stock Price (Quote)
$1.93
-0.0700 (-3.50%)
At Close: Sep 22, 2023
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $1.88 | $2.20 | Friday, 22nd Sep 2023 ABUS stock ended at $1.93. This is 3.5% less than the trading day before Wednesday, 20th Sep 2023. During the day the stock fluctuated 4.70% from a day low at $1.88 to a day high of $1.97. |
| 90 days | $1.88 | $2.39 | |
| 52 weeks | $1.85 | $3.15 |
Historical Arbutus Biopharma Corporation prices
| Date | Open | High | Low | Close | Volume |
| 2023-09-22 | $1.97 | $1.97 | $1.88 | $1.93 | 1 127 366 |
| 2023-09-20 | $1.98 | $2.03 | $1.98 | $2.00 | 445 670 |
| 2023-09-19 | $1.99 | $2.00 | $1.96 | $1.98 | 459 255 |
| 2023-09-18 | $2.02 | $2.04 | $1.98 | $1.99 | 543 078 |
| 2023-09-15 | $2.05 | $2.07 | $2.00 | $2.04 | 1 221 218 |
| 2023-09-14 | $2.03 | $2.08 | $2.03 | $2.05 | 408 659 |
| 2023-09-13 | $2.04 | $2.06 | $2.01 | $2.05 | 627 471 |
| 2023-09-12 | $2.19 | $2.19 | $2.02 | $2.03 | 774 180 |
| 2023-09-11 | $2.13 | $2.20 | $2.11 | $2.20 | 894 685 |
| 2023-09-08 | $2.05 | $2.11 | $2.04 | $2.10 | 657 412 |
| 2023-09-07 | $2.08 | $2.08 | $2.05 | $2.08 | 629 255 |
| 2023-09-06 | $2.03 | $2.10 | $2.02 | $2.08 | 472 945 |
| 2023-09-05 | $2.04 | $2.05 | $2.02 | $2.04 | 592 818 |
| 2023-09-01 | $2.03 | $2.06 | $2.02 | $2.05 | 728 897 |
| 2023-08-31 | $2.01 | $2.05 | $2.01 | $2.03 | 571 187 |
| 2023-08-30 | $2.02 | $2.05 | $2.00 | $2.02 | 516 704 |
| 2023-08-29 | $2.02 | $2.03 | $2.01 | $2.03 | 377 248 |
| 2023-08-28 | $2.03 | $2.05 | $2.01 | $2.02 | 227 833 |
| 2023-08-25 | $2.04 | $2.05 | $2.01 | $2.03 | 290 522 |
| 2023-08-24 | $2.03 | $2.06 | $2.02 | $2.05 | 582 192 |
| 2023-08-23 | $2.04 | $2.09 | $2.03 | $2.05 | 514 658 |
| 2023-08-22 | $2.05 | $2.11 | $2.04 | $2.05 | 474 359 |
| 2023-08-21 | $2.04 | $2.08 | $2.01 | $2.05 | 696 331 |
| 2023-08-18 | $2.05 | $2.12 | $2.04 | $2.06 | 497 636 |
| 2023-08-17 | $2.02 | $2.15 | $2.01 | $2.07 | 1 610 189 |
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ... ABUS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
